NAMS logo

NAMS
NewAmsterdam Pharma Company NV

482
Mkt Cap
$4.18B
Volume
583,591.00
52W High
$42.21
52W Low
$16.79
PE Ratio
-19.64
NAMS Fundamentals
Price
$35.44
Prev Close
$35.74
Open
$35.86
50D MA
$32.67
Beta
1.09
Avg. Volume
897,593.33
EPS (Annual)
-$1.72
P/B
6.21
Rev/Employee
$225,030.00
$3,516.96
Loading...
Loading...
News
all
press releases
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of +13.66% and +35.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
More News
News Placeholder
Pictet Asset Management Holding SA Lowers Position in NewAmsterdam Pharma Company N.V. $NAMS
Pictet Asset Management Holding SA trimmed its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 42.3% in the 4th quarter, according to the company in its most...
News Placeholder
Jennison Associates LLC Trims Stock Position in NewAmsterdam Pharma Company N.V. $NAMS
Jennison Associates LLC trimmed its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 16.9% during the 4th quarter, according to the company in its most recent...
News Placeholder
NewAmsterdam Pharma (NAMS) Expected to Announce Earnings on Thursday
NewAmsterdam Pharma (NASDAQ:NAMS) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
News Placeholder
143,549 Shares in NewAmsterdam Pharma Company N.V. $NAMS Bought by Moody Aldrich Partners LLC
Moody Aldrich Partners LLC bought a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 143,549 shares of the company's stock, valued at approximately...
News Placeholder
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 8% - What's Next?
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 8% - Should You Sell...
News Placeholder
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Rating of "Moderate Buy" from Analysts
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twelve analysts that are currently covering the company...
News Placeholder
Aberdeen Group plc Has $25.59 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS
Aberdeen Group plc grew its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 10.2% during the fourth quarter, according to its most recent disclosure with the Securities...
News Placeholder
JPMorgan Chase & Co. Trims Stock Position in NewAmsterdam Pharma Company N.V. $NAMS
JPMorgan Chase & Co. cut its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 10.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,302,498 shares of the company's stock after sell...
News Placeholder
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Truist Financial
Truist Financial assumed coverage on NewAmsterdam Pharma in a research report on Wednesday. They set a "buy" rating and a $57.00 price target on the stock...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available